Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Autoimmunity in Inner Ear Disease






The purpose of this study is to determine whether prednisone, methotrexate, and cyclophosphamide are effective in the treatment of rapidly progressive sensorineural hearing loss in both ears. This condition is called autoimmune inner ear disease (AIED), because it is thought that the hearing loss is triggered by an autoimmune process. Treatment attempts to suppress or control this process with powerful anti-inflammatory drugs. This is a Phase III, outpatient study. All study participants will be assigned to one of four different groups testing the experimental use of drugs. The study is scheduled to run for 18 months, with a minimum of 11 visits per participant.

Study Status: Terminated


Condition Intervention Phase
Hearing Loss, Sensorineural Drug: Corticosteroids
Drug: Methotrexate
Phase 3

Verified by National Institute on Deafness and Other Communication Disorders (NIDCD) April, 2006

Sponsored by: National Institute on Deafness and Other Communication Disorders (NIDCD)
Information provided by: National Institute on Deafness and Other Communication Disorders (NIDCD) identifier: NCT00000361

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study

Cleveland Clinic Foundation
Cleveland, Ohio 44195-5245
United States

Dr. Jeffrey Harris., Study Chair
Dr. Patrick Brookhouser., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site